Related Experiment Video
Updated: Aug 9, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions
Samuel Cos1, Alicia González, Carlos Martínez-Campa
1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, 39011 Santander, Spain. coss@unican.es
Background:
Melatonin exerts oncostatic effects on different kinds of tumors, especially on endocrine-responsive breast cancer. The most common conclusion is that melatonin reduces the incidence and growth of chemically induced mammary tumors, in vivo, and inhibits the proliferation and metastatic behavior of human breast cancer cells, in vitro. Both studies support the hypothesis that melatonin oncostatic actions on hormone-dependent mammary tumors are mainly based on its anti-estrogenic actions.
Methods And Results:
Two different mechanisms have been proposed to explain how melatonin reduces the development of breast cancer throughout its interactions with the estrogen-signaling pathways: (a) the indirect neuroendocrine mechanism which includes the melatonin down-regulation of the hypothalamic-pituitary reproductive axis and the consequent reduction of circulating levels of gonadal estrogens and (b) direct melatonin actions at tumor cell level. Melatonin's direct effect on mammary tumor cells is that it interferes with the activation of the estrogen receptor, thus behaving as a selective estrogen receptor modulator. Melatonin also regulates the activity of the aromatases, the enzymes responsible for the local synthesis of estrogens, thus behaving as a selective estrogen enzyme modulator.
Conclusions:
The same molecule has both properties to selectively neutralize the effects of estrogens on the breast and the local biosynthesis of estrogens from androgens, one of the main objectives of recent antitumor pharmacological therapeutic strategies. It is these action mechanisms that collectively make melatonin an interesting anticancer drug in the prevention and treatment of estrogen-dependent tumors, since it has the advantage of acting at different levels of the estrogen-signaling pathways.
Insights
Melatonin shows oncostatic effects against breast cancer by reducing estrogen signaling. It acts both indirectly by lowering estrogen levels and directly by interfering with estrogen receptors and synthesis.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Melatonin demonstrates oncostatic properties against various tumors, particularly endocrine-responsive breast cancer.
- Studies indicate melatonin reduces mammary tumor incidence and growth in vivo, and inhibits breast cancer cell proliferation and metastasis in vitro.
- These effects are primarily attributed to melatonin's anti-estrogenic actions on hormone-dependent mammary tumors.
Purpose of the Study:
- To elucidate the mechanisms by which melatonin reduces breast cancer development through its interaction with estrogen-signaling pathways.
- To explore both indirect neuroendocrine and direct cellular mechanisms of melatonin's oncostatic effects.
Main Methods:
- Investigated indirect mechanisms involving melatonin's down-regulation of the hypothalamic-pituitary reproductive axis, leading to reduced circulating estrogen levels.
- Examined direct cellular mechanisms, including melatonin's interference with estrogen receptor activation (acting as a selective estrogen receptor modulator).
- Assessed melatonin's regulation of aromatase activity, impacting local estrogen synthesis (acting as a selective estrogen enzyme modulator).
Main Results:
- Melatonin effectively reduces circulating estrogen levels via indirect neuroendocrine pathways.
- Melatonin directly inhibits estrogen receptor activation in mammary tumor cells.
- Melatonin modulates aromatase activity, decreasing local estrogen biosynthesis.
Conclusions:
- Melatonin possesses dual properties to counteract estrogen effects on breast tissue and inhibit local estrogen biosynthesis.
- These mechanisms position melatonin as a promising anticancer agent for preventing and treating estrogen-dependent tumors.
- Melatonin's ability to target multiple levels of estrogen-signaling pathways enhances its therapeutic potential.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Endocrine Signaling
Endocrine Signaling
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

